News

Screening test hope for bone disease

Scientists have discovered three genes linked to the development of Paget’s disease, a painful bone condition.

The international team of scientists, led by the University, believes the genes are involved in regulating the rate at which bone is repaired, providing an explanation of why the disease might occur.

Paget’s disease affects up to one million people in the UK.

The condition disrupts the body’s normal process of breaking down old bone and replacing it.

It affects more people in the UK than anywhere else in the world.

International study

Researchers - funded by Arthritis Research UK and Paget Association UK - studied the genes of 1250 patients with Paget’s disease to find the genes that could cause the condition.

The team - which included scientists from Spain, UK, New Zealand, and Australia - found that three genes that were faulty more frequently in patients with the bone disease than in healthy people.

Together, the faulty genes accounted for the development of Paget's disease in about 70 per cent of cases.

The results - published in the journal Nature Genetics - confirm that genes play a crucial role in the development of Paget’s disease, which explains why many patients have a family history of the condition.

It is hoped that the discovery will allow early detection of the disease and allow doctors to give preventative treatment before bones have become damaged.

These findings represent a major advancement to our understanding of the disease since, until now, only one gene was known to cause about 10 per cent of cases with Paget's disease. The three genes identified from this study contribute to 70 per cent of the disease risk – quiet unusual in common diseases.

Dr Omar AlbaghaSenior Lecturer, Institute for Genetics and Molecular Medicine

Professor Stuart Ralston, Arthritis Research UK Professor of Rheumatology, who led the study at the University of Edinburgh, said: “Our work shows that these three genes together very strongly predict the development of Paget's disease. Their effects are so powerful that they could be of real value in screening for risk of the disease.

"This is important since we know that if treatment is left too late, then irreversible damage to the bones can occur. If we were able to intervene at an early stage with preventative therapy, guided by genetic profiling, this would be a major advance."